AnaptysBio

$26.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.48 (+1.87%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AnaptysBio and other stocks, options, and ETFs commission-free!

About ANAB

AnaptysBio, Inc. Common Stock, also called AnaptysBio, is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA. The listed name for ANAB is AnaptysBio, Inc. Common Stock.

CEO

Hamza Suria

Employees

Headquarters

San Diego, California

Founded

2005

Market Cap

665.30M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

534.91K

High Today

$27.32

Low Today

$25.81

Open Price

$26.47

Volume

461.60K

52 Week High

$31.29

52 Week Low

$12.06

Collections

Analyst Ratings

33%

of 6 ratings

Buy

33%

Hold

50%

Sell

17%

ANAB Earnings

-$1.20

-$0.80

-$0.40

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 1, After Hours